retatrutide nonalcoholic steatohepatitis trial Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment NASH Study | Fatty Liver

Shifts in hormones, metabolism, and body composition can make this transition especially difficult for weight management

The 24.2% weight reduction at 48 weeks, combined with improvements in triglycerides, liver enzymes, and insulin sensitivity markers, positions Retatrutide as the more mechanistically complete compound in the Retatrutide vs Tirzepatide framework, pending Phase 3 confirmation

Side effects can be managed: Eat only when you're hungry

H., Lopez-Ferreras, L., Olandersson, K

In the diabetes and weight-loss drug market, smaller companies are in the mix when it comes to getting new treatments through the development and approval process

NIDDK Emerging Therapies and Oral GLP-1 Options Eli Lillys development of orforglipron, an oral GLP-1 receptor agonist, marks a significant advancement in diabetes treatment